Navigation Links
The Genome Analysis Center Selects Convey to Support Next-Generation Sequencing
Date:1/29/2013

Richardson, TX (PRWEB) January 29, 2013

Convey Computer today announced that The Genome Analysis Center (TGAC), one of seven institutes that receives strategic funding from the U.K.’s Biotechnology and Biological Sciences Research Council (BBSRC), has deployed two Convey HC-1ex hybrid-core systems for advanced genomics research. TGAC, based in the U.K., is an aggressive adopter of advanced sequencing and IT technology.

The two Convey HC-1ex systems are the latest addition to TGAC’s powerful computing infrastructure. By installing hybrid-core Convey HC-1ex systems, TGAC expanded their cluster and ccNUMA-based HPC environment to include leading edge heterogeneous computing capabilities.

“We need to analyze data quickly and precisely, which takes time on clusters,” explained Dr. Mario Caccamo, Deputy Director of TGAC. “We offloaded some of our sequence alignment demand to the Convey hybrid-core systems, because they can handle the alignment algorithms much more efficiently. Using the Convey systems, we are seeing up to 15x acceleration on our computationally intense BWA(1) runs.”

TGAC was part of an international team that recently demonstrated next-generation sequencing could be used effectively to fine map genes in polyploidy wheat. TGAC will leverage Convey’s architecture to accelerate computationally challenging jobs, such as resequencing alignment for wheat and other polyploidy species.

“The initial performance jump is a major improvement,” continued Dr. Caccamo. “We expect to achieve even better performance as we gain experience using the Convey platform.”

Convey’s hybrid-core architectur
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Whole Genome Sequencing of Triple Negative Breast Cancer Reveals Previously Unreported Mutations
2. Pig genome offers insights into the feistiest of farm animals
3. Researchers unlock disease information hidden in genomes control circuitry
4. In massive genome analysis ENCODE data suggests gene redefinition
5. Millions of DNA switches that power human genomes operating system are discovered
6. Human Genome Decoder and Artificial Life Creator, J. Craig Venter to Speak at "The Atlantic Meets the Pacific"
7. GenScript to Synthesize Yeast Genome with Johns Hopkins Scientists
8. Little known pregnancy disease, Hyperemesis Gravidarum, receives awareness with a $20,000 donation from the H.E.R. Foundation to begin Genome Research at UCLA
9. Two Blades Foundation licenses genome engineering technology to KWS
10. The Human Genome Is Displayed in the Dimension of Time in Web-Based Exhibition by Yonder Biology
11. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
Rabbit polyclonal to hnRNP-U...
... DNase I (RNase-free) (E.C. 3.1.21.1) is ... DNA and chromatin. It functions by hydrolyzing ... a 5'-phosphate and a 3'-hydroxyl group. Ambion's ... purity available and is recommended to degrade ...
... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
Biology Products: